Structure‐Based Design and Synthesis of the First Weak Non‐Phosphate Inhibitors for IspF, an Enzyme in the Non‐Mevalonate Pathway of Isoprenoid Biosynthesis
暂无分享,去创建一个
[1] Markus Fischer,et al. Nonmevalonate terpene biosynthesis enzymes as antiinfective drug targets: substrate synthesis and high-throughput screening methods. , 2006, The Journal of organic chemistry.
[2] J. Wiesner,et al. Synthesis of α-aryl-substituted and conformationally restricted fosmidomycin analogues as promising antimalarials , 2006 .
[3] J. Wiesner,et al. Fosmidomycin plus Clindamycin for Treatment of Pediatric Patients Aged 1 to 14 Years with Plasmodium falciparum Malaria , 2006, Antimicrobial Agents and Chemotherapy.
[4] J. Wiesner,et al. Synthesis and biological evaluation of cyclopropyl analogues of fosmidomycin as potent Plasmodium falciparum growth inhibitors. , 2006, Journal of medicinal chemistry.
[5] François Diederich,et al. Aushungern des Malaria-Erregers: Hemmer der Aspartylproteasen Plasmepsin I, II und IV† , 2006 .
[6] F. Diederich,et al. Starving the malaria parasite: inhibitors active against the aspartic proteases plasmepsins I, II, and IV. , 2006, Angewandte Chemie.
[7] F. Diederich,et al. Bisubstrate Inhibitors of Catechol O‐Methyltransferase (COMT): the Crucial Role of the Ribose Structural Unit for Inhibitor Binding Affinity , 2006, ChemMedChem.
[8] L. McLaughlin,et al. Syntheses of pyridine C-nucleosides as analogues of the natural nucleosides dC and dU. , 2006, The Journal of organic chemistry.
[9] K. Jacobson,et al. Adenosine receptors as therapeutic targets , 2006, Nature Reviews Drug Discovery.
[10] A. Bacher,et al. Fluoreszierende Inhibitoren von IspF, einem Enzym im “Nicht‐Mevalonat‐Biosyntheseweg” der Isoprenoide und möglichen Ziel einer Antimalariatherapie , 2006 .
[11] F. Diederich,et al. Fluorescent inhibitors for IspF, an enzyme in the non-mevalonate pathway for isoprenoid biosynthesis and a potential target for antimalarial therapy. , 2006, Angewandte Chemie.
[12] A. Thayer. FIGHTING MALARIA: New antimalarial drugs are needed to ensure that effective and affordable treatments continue to be available and are not lost to parasite resistance , 2005 .
[13] N. Ramsden,et al. A double mutation of Escherichia coli2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase disrupts six hydrogen bonds with, yet fails to prevent binding of, an isoprenoid diphosphate. , 2005, Acta crystallographica. Section F, Structural biology and crystallization communications.
[14] Charles P. Casey,et al. COMMENT: THE ACS ACADEMIC EMPLOYMENT INITIATIVE , 2005 .
[15] Andrew D. Miller,et al. The facile preparation of primary and secondary amines via an improved Fukuyama-Mitsunobu procedure. Application to the synthesis of a lung-targeted gene delivery agent. , 2005, Organic & biomolecular chemistry.
[16] W. Eisenreich,et al. The identification of isoprenoids that bind in the intersubunit cavity of Escherichia coli 2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase by complementary biophysical methods. , 2005, Acta crystallographica. Section D, Biological crystallography.
[17] D. Bussiere,et al. Structure of 2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase from Shewanella oneidensis at 1.6 A: identification of farnesyl pyrophosphate trapped in a hydrophobic cavity. , 2004, Acta crystallographica. Section D, Biological crystallography.
[18] H. Jomaa,et al. Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria. , 2004, The Journal of infectious diseases.
[19] E. Oldfield,et al. Inhibition of isoprene biosynthesis pathway enzymes by phosphonates, bisphosphonates, and diphosphates. , 2004, Journal of medicinal chemistry.
[20] A. Bacher,et al. Biosynthesis of isoprenoids via the non-mevalonate pathway , 2004, Cellular and Molecular Life Sciences CMLS.
[21] T. Kinoshita,et al. Structure-based design and synthesis of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors. , 2004, Journal of medicinal chemistry.
[22] J. Wiesner,et al. Neue Antimalaria‐Wirkstoffe , 2003 .
[23] Jochen Wiesner,et al. New antimalarial drugs. , 2003, Angewandte Chemie.
[24] M. Faust,et al. Cytosine analogues from substituted acetonitriles via Thorpe condensation. , 2003, Organic letters.
[25] J. Wiesner,et al. Fosmidomycin for the treatment of malaria , 2003, Parasitology Research.
[26] Jochen Wiesner,et al. Fosmidomycin, a Novel Chemotherapeutic Agent for Malaria , 2003, Antimicrobial Agents and Chemotherapy.
[27] S. Katayama,et al. Tricyclic indole-2-carboxylic acids: highly in vivo active and selective antagonists for the glycine binding site of the NMDA receptor. , 2003, Journal of medicinal chemistry.
[28] W. Eisenreich,et al. The deoxyxylulose phosphate pathway of isoprenoid biosynthesis. Discovery and function of the ispDEFGH genes and their cognate enzymes , 2003 .
[29] S. Yokoyama,et al. Structure and catalytic mechanism of 2-C-methyl-D-erythritol 2,4-cyclodiphosphate (MECDP) synthase, an enzyme in the non-mevalonate pathway of isoprenoid synthesis. , 2003, Acta crystallographica. Section D, Biological crystallography.
[30] A. Kuki,et al. Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide. , 2002, Journal of medicinal chemistry.
[31] E. Lesnik,et al. High-affinity peptide nucleic acid oligomers containing tricyclic cytosine analogues. , 2002, Organic letters.
[32] E. Eisenstein,et al. Structure of 2C‐methyl‐D‐erythrol‐2,4‐cyclodiphosphate synthase from Haemophilus influenzae: Activation by conformational transition , 2002, Proteins.
[33] E. Negishi. Handbook of organopalladium chemistry for organic synthesis , 2002 .
[34] Charles S Bond,et al. Structure of 2C-methyl-d-erythritol 2,4- cyclodiphosphate synthase: An essential enzyme for isoprenoid biosynthesis and target for antimicrobial drug development , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[35] A. Linden,et al. Synthesis of Bis(2,4-diarylimidazol-5-yl) Diselenides from N-Benzylbenzimidoyl Isoselenocyanates , 2002 .
[36] D. Cane,et al. Structure and Mechanism of 2-C-Methyl-d-erythritol 2,4-Cyclodiphosphate Synthase , 2002, The Journal of Biological Chemistry.
[37] S. Steinbacher,et al. Structure of 2C-methyl-d-erythritol-2,4-cyclodiphosphate synthase involved in mevalonate-independent biosynthesis of isoprenoids. , 2002, Journal of molecular biology.
[38] B. Greenwood,et al. Malaria in 2002 , 2002, Nature.
[39] Robert G. Ridley,et al. Medical need, scientific opportunity and the drive for antimalarial drugs , 2002, Nature.
[40] S. Buchwald,et al. Practical Palladium Catalysts for C-N and C-O Bond Formation , 2002 .
[41] S. Buchwald,et al. A general and efficient copper catalyst for the amidation of aryl halides and the N-arylation of nitrogen heterocycles. , 2001, Journal of the American Chemical Society.
[42] A. Bridges,et al. Chemical inhibitors of protein kinases. , 2001, Chemical reviews.
[43] I. Kuntz,et al. Adenosine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of Trypanosomatidae via structure-based drug design. , 2001, Journal of medicinal chemistry.
[44] W. Eisenreich,et al. Biosynthesis of terpenoids. 2C-Methyl-D-erythritol 2,4-cyclodiphosphate synthase (IspF) from Plasmodium falciparum. , 2001, European journal of biochemistry.
[45] E. De Clercq,et al. Chiral synthesis of 4-[1-(2-deoxy-beta-L-ribofuranosyl)] derivatives of 2-substituted 5-fluoroaniline: "cytosine replacement" analogues of deoxy-beta-L-cytidine. , 2000, The Journal of organic chemistry.
[46] D Shugar,et al. Purine nucleoside phosphorylases: properties, functions, and clinical aspects. , 2000, Pharmacology & therapeutics.
[47] T. Fujiwara,et al. Molecular design, synthesis, and hypoglycemic activity of a series of thiazolidine-2,4-diones. , 2000, Journal of medicinal chemistry.
[48] W. Eisenreich,et al. Biosynthesis of terpenoids: YgbB protein converts 4-diphosphocytidyl-2C-methyl-D-erythritol 2-phosphate to 2C-methyl-D-erythritol 2,4-cyclodiphosphate. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[49] H. Lichtenthaler,et al. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. , 1999, Science.
[50] Paul R. Gerber,et al. MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry , 1995, J. Comput. Aided Mol. Des..
[51] R. H. Berg,et al. Synthesis of Peptide Nucleic Acid Monomers Containing the Four Natural Nucleobases: Thymine, Cytosine, Adenine, and Guanine and Their Oligomerization , 1994 .
[52] S. Shibuya,et al. Group IV-Metal-Catalyzed Aminolysis of N-Acyl-2-oxazolidinones: Applications to the Chemoselective and Enantioselective Carbonylation of Primary Alkylamines , 1994 .
[53] H. Sahm,et al. Isoprenoid biosynthesis in bacteria: a novel pathway for the early steps leading to isopentenyl diphosphate. , 1993, The Biochemical journal.
[54] Y. Mizuno,et al. Studies on the chemical synthesis of potential antimetabolites. 30. Regioselective introduction of a chlorine atom into the imidazo[4,5-b]pyridine nucleus† , 1982 .
[55] C. Danzin,et al. Synthesis and biochemical properties of chemically stable product analogues of the reaction catalyzed by S-adenosyl-L-methionine decarboxylase. , 1982, Journal of medicinal chemistry.
[56] O. Mitsunobu. The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products , 1981 .
[57] R. Middleton,et al. Synthesis of imidazo[4,5-b]- and [4,5-c]pyridines , 1980 .